Takeda faces major AMITIZA antitrust verdict and prepares FY2025 provision

Takeda Pharmaceutical Co ( (JP:4502) ) just unveiled an announcement.

Takeda said a Massachusetts jury returned a verdict against the company in U.S. antitrust litigation over the constipation drug AMITIZA, awarding nearly USD 885 million in single damages to wholesalers, retailers and end payors, with certain portions subject to automatic trebling. The company disputes the outcome, arguing its 2014 patent settlement over AMITIZA’s generic entry was lawful and stressing that any final liability, potential provision size and impact on its financial statements will depend on post-trial proceedings and appeals.

The drugmaker plans to recognize a provision related to the case in its FY2025 consolidated results and will restate that year’s earnings and financial materials once the amount is set, although it expects no effect on FY2025 core figures. Takeda does not foresee a material hit to its FY2026 outlook beyond possible changes to adjusted free cash flow, but signaled it may revise guidance once it completes its assessment and clarifies the timing and scale of any cash payments.

The most recent analyst rating on (JP:4502) stock is a Buy with a Yen6900.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.

More about Takeda Pharmaceutical Co

Takeda Pharmaceutical Co. is a Japan-headquartered, R&D-driven biopharmaceutical company focused on gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. It operates globally in about 80 countries, aiming to deliver life-transforming treatments through a broad pipeline developed in partnership with external collaborators.

Average Trading Volume: 4,511,087

Technical Sentiment Signal: Buy

Current Market Cap: Yen8365.2B

See more insights into 4502 stock on TipRanks’ Stock Analysis page.